Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.
Dr. Jennifer Chan
Advertisement
Dr. Jennifer Chan is clinical director of the Gastrointestinal Cancer Center and director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute in Boston.
Articles by Dr. Jennifer Chan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
2
Facing Mortality After Cancer, and Choosing to Live Fully
3
Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer
4
Imfinzi Combo Improves Progression Free Survival in Ovarian Cancer
5
